Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Neoplasms of the CNS

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 76 articles:
HTML format
Text format



Single Articles


    February 2017
  1. BLOCH O, Lim M, Sughrue ME, Komotar RJ, et al
    Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy.
    Clin Cancer Res. 2017 Feb 13. pii: clincanres.1369.2016.
    PubMed     Text format     Abstract available


    December 2016
  2. HOLDHOFF M, Guner G, Rodriguez FJ, Hicks JL, et al
    Absence of cytomegalovirus in glioblastoma and other high-grade gliomas by real-time PCR, immunohistochemistry and in situ hybridization.
    Clin Cancer Res. 2016 Dec 29. pii: clincanres.1490.2016.
    PubMed     Text format     Abstract available


  3. PORTNOW J, Synold TW, Badie B, Tirughana R, et al
    Neural stem cell-based anti-cancer gene therapy: a first-in-human study in recurrent high grade glioma patients.
    Clin Cancer Res. 2016 Dec 15. pii: clincanres.1518.2016.
    PubMed     Text format     Abstract available


    November 2016
  4. WANG Z, Hao Y, Zhang CB, Wang Z, et al
    The landscape of viral expression reveals clinically relevant viruses with potential capability of promoting malignancy in lower grade glioma.
    Clin Cancer Res. 2016 Nov 18. pii: clincanres.1495.2016.
    PubMed     Text format     Abstract available


  5. DADEY DY, Kapoor V, Hoye K, Khudanyan A, et al
    Antibody targeting GRP78 enhances the efficacy of radiation therapy in human glioblastoma and non-small-cell lung cancer cell lines and tumor models.
    Clin Cancer Res. 2016 Nov 4. pii: clincanres.1935.2016.
    PubMed     Text format     Abstract available


    October 2016
  6. ELLIOTT JT, Marra K, Evans LT, Davis SC, et al
    Simultaneous in vivo fluorescent markers for perfusion, protoporphyrin metabolism and EGFR expression for optically guided identification of orthotopic glioma.
    Clin Cancer Res. 2016 Oct 31. pii: clincanres.1400.2016.
    PubMed     Text format     Abstract available


  7. KICKINGEREDER P, Gotz M, Muschelli J, Wick A, et al
    Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response.
    Clin Cancer Res. 2016.
    PubMed     Text format     Abstract available


  8. STEEG PS, Zimmer AS, Gril B
    Therapeutics for Brain Metastases, Version 3.
    Clin Cancer Res. 2016 Oct 10. pii: clincanres.2035.2016.
    PubMed     Text format     Abstract available


    September 2016
  9. RAMACHANDRAN M, Yu D, Dyczynski M, Baskaran S, et al
    Safe and effective treatment of experimental neuroblastoma and glioblastoma using systemically administered triple microRNA-detargeted oncolytic Semliki Forest virus.
    Clin Cancer Res. 2016 Sep 16. pii: clincanres.0925.2016.
    PubMed     Text format     Abstract available


  10. POINTER KB, Clark PA, Eliceiri KW, Salamat MS, et al
    Non-torsadogenic human Ether-a-go-go Related Gene (hERG) inhibitors are associated with better survival for high hERG-expressing glioblastoma patients.
    Clin Cancer Res. 2016 Sep 15. pii: clincanres.3169.2016.
    PubMed     Text format     Abstract available


    August 2016
  11. LIN F, de Gooijer MC, Hanekamp D, Chandrasekaran G, et al
    PI3K-mTOR pathway inhibition exhibits efficacy against high-grade glioma in clinically relevant mouse models.
    Clin Cancer Res. 2016 Aug 23. pii: clincanres.1276.2016.
    PubMed     Text format     Abstract available


  12. CALINESCU AA, Yadav VN, Carballo E, Kadiyala P, et al
    Survival and proliferation of neural progenitor derived glioblastomas under hypoxic stress is controlled by a CXCL12/CXCR4 autocrine positive feedback mechanism.
    Clin Cancer Res. 2016 Aug 19. pii: clincanres.2888.2015.
    PubMed     Text format     Abstract available


  13. WINKLER F, Osswald M, Blaes J, Liao Y, et al
    Impact of blood-brain barrier integrity on tumor growth and therapy response in brain metastases.
    Clin Cancer Res. 2016 Aug 12. pii: clincanres.1327.2016.
    PubMed     Text format     Abstract available


  14. REINARTZ R, Wang S, Kebir S, Silver DJ, et al
    FUNCTIONAL SUBCLONE PROFILING FOR PREDICTION OF TREATMENT-INDUCED INTRA-TUMOR POPULATION SHIFTS AND DISCOVERY OF RATIONAL DRUG COMBINATIONS IN HUMAN GLIOBLASTOMA.
    Clin Cancer Res. 2016 Aug 12. pii: clincanres.2089.2015.
    PubMed     Text format     Abstract available


  15. LOWENSTEIN PR, Castro MG
    Multiple expressed endogenous glioma epitopes as novel vaccines for gliomas.
    Clin Cancer Res. 2016 Aug 12. pii: clincanres.1477.2016.
    PubMed     Text format     Abstract available


    July 2016
  16. BALLARD P, Yates JW, Yang Z, Kim DW, et al
    Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
    Clin Cancer Res. 2016 Jul 19. pii: clincanres.0399.2015.
    PubMed     Text format     Abstract available


    June 2016
  17. KIM JE, Patel MA, Mangraviti A, Kim ES, et al
    Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas.
    Clin Cancer Res. 2016 Jun 29. pii: clincanres.1535.2015.
    PubMed     Text format     Abstract available


  18. KALININA J, Ahn J, Devi NS, Wang L, et al
    Selective detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of glioma patients with mutated Isocitrate Dehydrogenase.
    Clin Cancer Res. 2016 Jun 23. pii: clincanres.2965.2015.
    PubMed     Text format     Abstract available


  19. NIESSNER H, Schmitz J, Tabatabai G, Schmid A, et al
    PI3K pathway inhibition achieves potent antitumor activity in melanoma brain metastases in vitro and in vivo.
    Clin Cancer Res. 2016 Jun 15. pii: clincanres.0064.2016.
    PubMed     Text format     Abstract available


  20. GENG F, Cheng X, Wu X, Yoo JY, et al
    Inhibition of SOAT1 suppresses glioblastoma growth via blocking SREBP-1-mediated lipogenesis.
    Clin Cancer Res. 2016 Jun 8. pii: clincanres.2973.2015.
    PubMed     Text format     Abstract available


    May 2016
  21. LYLE LT, Lockman PR, Adkins CE, Mohammad AS, et al
    Alterations in Pericyte Subpopulations are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer.
    Clin Cancer Res. 2016 May 31. pii: clincanres.1836.2015.
    PubMed     Text format     Abstract available


  22. RAMPLING R, Peoples S, Mulholland PJ, James A, et al
    A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multi Peptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma.
    Clin Cancer Res. 2016 May 25. pii: clincanres.0506.2016.
    PubMed     Text format     Abstract available


  23. OLOW A, Mueller S, Yang X, Hashizume R, et al
    BRAF status in personalizing treatment approaches for pediatric gliomas.
    Clin Cancer Res. 2016 May 23. pii: clincanres.1101.2015.
    PubMed     Text format     Abstract available


  24. XU R, Shimizu F, Hovinga K, Beal K, et al
    Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial.
    Clin Cancer Res. 2016 May 6. pii: clincanres.0048.2016.
    PubMed     Text format     Abstract available


  25. WICK W, Gorlia T, Bady P, Platten M, et al
    Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082).
    Clin Cancer Res. 2016 May 3. pii: clincanres.3153.2015.
    PubMed     Text format     Abstract available



  26. Correction: Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas.
    Clin Cancer Res. 2016;22:2313.
    PubMed     Text format    


    April 2016
  27. TATEISHI K, Iafrate AJ, Ho Q, Curry WT, et al
    Myc-driven glycolysis is a therapeutic target in glioblastoma.
    Clin Cancer Res. 2016 Apr 13. pii: clincanres.2274.2015.
    PubMed     Text format     Abstract available


    March 2016
  28. LUN X, Wells JC, Grinshtein N, King JC, et al
    Disulfiram when combined with copper enhances the therapeutic effects of temozolomide for the treatment of Glioblastoma.
    Clin Cancer Res. 2016 Mar 22. pii: clincanres.1798.2015.
    PubMed     Text format     Abstract available


  29. YAO Y, Ye H, Qi Z, Mo L, et al
    B7-H4(B7x)-Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients.
    Clin Cancer Res. 2016.
    PubMed     Text format     Abstract available


  30. PALANICHAMY K, Thirumoorthy K, Kanji S, Gordon N, et al
    Methionine and Kynurenine Activate Oncogenic Kinases in Glioblastoma, and Methionine Deprivation Compromises Proliferation.
    Clin Cancer Res. 2016 Mar 2. pii: clincanres.2308.2015.
    PubMed     Text format     Abstract available


    February 2016
  31. CURRY WT, Gorrepati R, Piesche M, Sasada T, et al
    Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Anti-tumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.
    Clin Cancer Res. 2016 Feb 12. pii: clincanres.2163.2015.
    PubMed     Text format     Abstract available


    December 2015
  32. KEBIR S, Fimmers R, Galldiks N, Schaefer N, et al
    Late Pseudoprogression in glioblastoma: diagnostic value of dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET.
    Clin Cancer Res. 2015 Dec 16. pii: clincanres.1334.2015.
    PubMed     Text format     Abstract available


  33. MARTUSCELLO RT, Vedam-Mai V, McCarthy DJ, Schmoll ME, et al
    A Supplemented High-Fat Low-Carbohydrate Diet for the Treatment of Glioblastoma.
    Clin Cancer Res. 2015 Dec 2. pii: clincanres.0916.2015.
    PubMed     Text format     Abstract available


    November 2015
  34. MA Y, Tang N, Thompson RC, Mobley B, et al
    InsR/IGF1R pathway mediates resistance to EGFR inhibitors in glioblastoma.
    Clin Cancer Res. 2015 Nov 11. pii: clincanres.1677.2015.
    PubMed     Text format     Abstract available


  35. ANDRONESI OC, Loebel F, Bogner W, Marjanska M, et al
    Treatment response assessment in IDH-mutant glioma patients by non-invasive 3D functional Spectroscopic Mapping of 2-Hydroxyglutarate.
    Clin Cancer Res. 2015 Nov 3. pii: clincanres.0656.2015.
    PubMed     Text format     Abstract available


    October 2015
  36. HUANG RY, Rahman R, Ballman KV, Felten S, et al
    The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.
    Clin Cancer Res. 2015 Oct 21. pii: clincanres.3040.2014.
    PubMed     Text format     Abstract available


  37. JACKSON CM, Kochel CM, Nirschl CJ, Durham NM, et al
    Systemic Tolerance Mediated by Melanoma Brain Tumors is Reversible by Radiotherapy and Vaccination.
    Clin Cancer Res. 2015 Oct 21. pii: clincanres.1516.2015.
    PubMed     Text format     Abstract available


  38. VERREAULT M, Schmitt C, Goldwirt L, Pelton K, et al
    Preclinical efficacy of the MDM2 inhibitor RG7112 in MDM2 amplified and TP53 wild-type glioblastomas.
    Clin Cancer Res. 2015 Oct 19. pii: clincanres.1015.2015.
    PubMed     Text format     Abstract available


  39. MAR N, Desjardins A, Vredenburgh JJ
    CCR 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma-The Progress and the Limitations.
    Clin Cancer Res. 2015;21:4248-50.
    PubMed     Text format     Abstract available


    September 2015
  40. PHAM CD, Flores C, Yang C, Pinheiro EM, et al
    Differential immune microenvironments and response to immune checkpoint blockade amongst molecular subtypes of murine medulloblastoma.
    Clin Cancer Res. 2015 Sep 24. pii: clincanres.0713.2015.
    PubMed     Text format     Abstract available



  41. Correction: PID1 (NYGGF4), a New Growth-Inhibitory Gene in Embryonal Brain Tumors and Gliomas.
    Clin Cancer Res. 2015;21:4243.
    PubMed     Text format    


    July 2015
  42. SINGH SK, Venugopal C, Hallett R, Vora P, et al
    Pyrvinium targets CD133 in human glioblastoma brain tumor-initiating cells.
    Clin Cancer Res. 2015 Jul 7. pii: clincanres.3147.2014.
    PubMed     Text format     Abstract available


    June 2015
  43. KIM SJ, Lee HJ, Kim SW, Choi HJ, et al
    Macitentan, a dual endothelin receptor antagonist, in combination with temozolomide leads to glioblastoma regression and long-term survival in mice.
    Clin Cancer Res. 2015 Jun 23. pii: clincanres.3195.2014.
    PubMed     Text format     Abstract available


  44. HANNIFORD D, Zhong J, Koetz L, Gaziel-Sovran A, et al
    A miRNA-based signature detected in primary melanoma tissue predicts development of brain metastasis.
    Clin Cancer Res. 2015 Jun 18. pii: clincanres.2566.2014.
    PubMed     Text format     Abstract available


  45. BROWN CE, Badie B, Barish ME, Weng L, et al
    Bioactivity and Safety of IL13Ralpha2-Redirected Chimeric Antigen Receptor CD8+ T cells in Patients with Recurrent Glioblastoma.
    Clin Cancer Res. 2015 Jun 9. pii: clincanres.0428.2015.
    PubMed     Text format     Abstract available


    May 2015
  46. SHI Y, Chen C, Yu S, Liu Q, et al
    miR-663 suppresses oncogenic function of CXCR4 in glioblastoma.
    Clin Cancer Res. 2015 May 28. pii: clincanres.2807.2014.
    PubMed     Text format     Abstract available



  47. Retraction: glioma-associated cancer-initiating cells induce immunosuppression.
    Clin Cancer Res. 2015;21:2189.
    PubMed     Text format    


    April 2015
  48. LEE EQ, Kaley TJ, Duda DG, Schiff D, et al
    A multicenter, phase II, randomized, non-comparative clinical trial of radiation and temozolomide with or without vandetanib in newly-diagnosed glioblastoma patients.
    Clin Cancer Res. 2015 Apr 24. pii: clincanres.3220.2014.
    PubMed     Text format     Abstract available


  49. LIU Y, Zhou R, Sulman EP, Scheurer ME, et al
    Genetic Modulation of Neurocognitive Function in Glioma Patients.
    Clin Cancer Res. 2015 Apr 22. pii: clincanres.0168.2015.
    PubMed     Text format     Abstract available


  50. ELLINGSON BM, Lai A, Nguyen HN, Nghiemphu PL, et al
    Quantification of nonenhancing tumor burden in gliomas using effective T2 maps derived from dual-echo turbo spin-echo MRI.
    Clin Cancer Res. 2015 Apr 21. pii: clincanres.2862.2014.
    PubMed     Text format     Abstract available


  51. BAI RY, Staedtke V, Wanjiku T, Rudek MA, et al
    Brain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model.
    Clin Cancer Res. 2015 Apr 10. pii: clincanres.2681.2014.
    PubMed     Text format     Abstract available


    March 2015
  52. MEISEN WH, Wohleb ES, Jaime-Ramirez AC, Bolyard CM, et al
    The impact of macrophage and microglia secreted TNFalpha on oncolytic HSV-1 therapy in the glioblastoma tumor microenvironment.
    Clin Cancer Res. 2015 Mar 31. pii: clincanres.3118.2014.
    PubMed     Text format     Abstract available


  53. KLUGER H, Zito CR, Barr M, Baine M, et al
    Characterization of PD-L1 Expression and Associated T cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.
    Clin Cancer Res. 2015 Mar 18. pii: clincanres.3073.2014.
    PubMed     Text format     Abstract available


    February 2015
  54. LU YS, Chen TW, Lin CH, Yeh DC, et al
    Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy.
    Clin Cancer Res. 2015 Feb 19. pii: clincanres.2075.2014.
    PubMed     Text format     Abstract available


  55. CARVAJAL RD, Lawrence DP, Weber J, Gajewski TF, et al
    Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.
    Clin Cancer Res. 2015 Feb 18. pii: clincanres.1630.2014.
    PubMed     Text format     Abstract available


  56. FINE HA
    New Strategies in Glioblastoma: Exploiting the New Biology.
    Clin Cancer Res. 2015 Feb 10. pii: clincanres.1328.2014.
    PubMed     Text format     Abstract available


  57. WELLER M, Tabatabai G, Kastner B, Felsberg J, et al
    MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial.
    Clin Cancer Res. 2015 Feb 5. pii: clincanres.2737.2014.
    PubMed     Text format     Abstract available



  58. Correction: Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors.
    Clin Cancer Res. 2015;21:662.
    PubMed     Text format    


    January 2015
  59. BESSE B, Le Moulec S, Maazieres J, Senellart H, et al
    Bevacizumab in Patients with Non-Squamous Non-Small-Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): a Non-Randomised, Phase II Study.
    Clin Cancer Res. 2015 Jan 22. pii: clincanres.2082.2014.
    PubMed     Text format     Abstract available


  60. POKORNY JL, Calligaris D, Gupta SK, Iyekegbe DO Jr, et al
    The efficacy of the Wee1 inhibitor MK-1775 combined with temozolomide is limited by heterogeneous distribution across the blood-brain barrier in glioblastoma.
    Clin Cancer Res. 2015 Jan 21. pii: clincanres.2588.2014.
    PubMed     Text format     Abstract available


  61. DI STEFANO AL, Fucci A, Frattini V, Labussiere M, et al
    Detection, characterization and inhibition of FGFR-TACC fusions in IDH wild type glioma.
    Clin Cancer Res. 2015 Jan 21. pii: clincanres.2199.2014.
    PubMed     Text format     Abstract available


  62. HOFER S, Mengele K, Schmitt M, Pestalozzi B, et al
    Complement activation and rituximab distribution in CNS NHL--letter.
    Clin Cancer Res. 2015;21:490.
    PubMed     Text format    


  63. MORENO L, Marshall LV, Pearson AD, Morland B, et al
    A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study.
    Clin Cancer Res. 2015;21:267-73.
    PubMed     Text format     Abstract available


  64. MERINO DM, Shlien A, Villani A, Pienkowska M, et al
    Molecular characterization of choroid plexus tumors reveals novel clinically relevant subgroups.
    Clin Cancer Res. 2015;21:184-92.
    PubMed     Text format     Abstract available


    December 2014
  65. LEE HW, Lee J, Lee SJ, Cho HJ, et al
    Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.
    Clin Cancer Res. 2014 Dec 30. pii: clincanres.1589.2014.
    PubMed     Text format     Abstract available


  66. SHOU Y, Robinson DM, Amakye DD, Rose KL, et al
    A Five-Gene Hedgehog Signature Developed as a Patient Preselection Tool for Hedgehog Inhibitor Therapy in Medulloblastoma.
    Clin Cancer Res. 2014 Dec 3. pii: clincanres.1711.2013.
    PubMed     Text format     Abstract available


    November 2014
  67. RODON J, Carducci MA, Sepulveda-Sanchez JM, Azaro A, et al
    First-in-Human Dose Study of the Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma.
    Clin Cancer Res. 2014 Nov 25. pii: clincanres.1380.2014.
    PubMed     Text format     Abstract available


  68. OKADA H, Butterfield LH, Hamilton RL, Hoji A, et al
    Induction of robust type-1 CD8+ T-cell responses in WHO grade II low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC.
    Clin Cancer Res. 2014 Nov 25. pii: clincanres.1790.2014.
    PubMed     Text format     Abstract available


  69. GAJJAR A, Pfister SM, Taylor MD, Gilbertson RJ, et al
    Molecular insights into pediatric brain tumors have the potential to transform therapy.
    Clin Cancer Res. 2014;20:5630-40.
    PubMed     Text format     Abstract available


  70. FECCI PE, Heimberger AB, Sampson JH
    Immunotherapy for primary brain tumors: no longer a matter of privilege.
    Clin Cancer Res. 2014;20:5620-9.
    PubMed     Text format     Abstract available


  71. BATCHELOR TT, Reardon DA, de Groot JF, Wick W, et al
    Antiangiogenic therapy for glioblastoma: current status and future prospects.
    Clin Cancer Res. 2014;20:5612-9.
    PubMed     Text format     Abstract available


  72. HUSE JT, Aldape KD
    The evolving role of molecular markers in the diagnosis and management of diffuse glioma.
    Clin Cancer Res. 2014;20:5601-11.
    PubMed     Text format     Abstract available


  73. GILBERT MR, Armstrong TS, Pope WB, van den Bent MJ, et al
    Facing the future of brain tumor clinical research.
    Clin Cancer Res. 2014;20:5591-600.
    PubMed     Text format     Abstract available


  74. HSIEH CH, Lin YJ, Wu CP, Lee HT, et al
    Livin contributes to tumor hypoxia-induced resistance to cytotoxic therapies in glioblastoma multiforme.
    Clin Cancer Res. 2014 Nov 4. pii: clincanres.0618.2014.
    PubMed     Text format     Abstract available


    May 2014
  75. CHEN G, Chakravarti N, Aardalen K, Lazar AJ, et al
    Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target.
    Clin Cancer Res. 2014.
    PubMed     Text format     Abstract available


    February 2014
  76. MENZIES AM, Long GV
    Dabrafenib and Trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Clin Cancer Res. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: